IHRA applies advanced thermal imaging, analyzed with AI and computer vision, to detect early patterns linked to Type 2 Diabetes, Hypertension, and Dyslipidemia. By enabling rapid, non-invasive risk assessment, IHRA helps clinicians act sooner and improve decision-making across the continuum of care.
Discover More
IHRA, developed by Aarca Research, revolutionizes early detection of metabolic conditions such as Type 2 Diabetes, Hypertension, and Dyslipidemia. Using proprietary software and a third-party thermal camera, IHRA provides risk scores that are crucial for early intervention and management.
Captures thermal signatures without invasive procedures.
Generates near-instant reports to support timely clinical decisions.
Detects subtle physiological changes that may indicate early vascular or metabolic risks.
Using proprietary software and a third-party thermal camera, IHRA provides risk scores that are crucial for early intervention and management.
Infrared thermal imaging with AI and computer vision–based analysis.
Secure integration with clinical workflows and EMRs.
Standardized thermal risk reports for clinicians and patients.
IHRA generates a combined visual and data-driven report, using thermal heat maps with quantified risk scoring. This dual format helps clinicians detect early signals of metabolic stress and vascular compromise while improving communication and patient engagement.
NerveVue delivers an innovative, non-invasive solution for the early detection of Peripheral Artery Disease (PAD), driving earlier intervention, improved outcomes, and cost efficiency across the continuum of care.
Setup
Scan
Analyze
Decide
We are extending our heartfelt appreciation for your exceptional dedication and success in
conducting the IHRA pilot project for non-invasive screening of Type 2 Diabetes, Hypertension, and
Dyslipidemia at KEM Hospital. Your hard work has yielded remarkable results and insights, reaffirming our
commitment to innovative healthcare solutions.
Your collaborative approach and unwavering focus on improving healthcare are inspiring. This will provide
us with the opportunity to build upon the accomplishments of the pilot and continue our pursuit of
meaningful advancements in patient care.
Thank you for your valuable contributions.
The method and screening conducted by the Aarca Research team using a thermal camera are unique and we have come across such technology for the first time. The reports and results published by your team is matching with the health condition of the individuals. We also received positive feedback from the team and the individuals who attended this camp and completed the screenings. We are sure all your endeavours in the coming years will lead to demonstrating more of such commendable initiatives.
IHRA is an effective and reliable solution for the early detection of metabolic comorbidities such as Type II Diabetes, Hypertension and Dyslipidemia. IHRA can be used as a screening tool for the early detection of the onset of these conditions and to inform the healthcare personnel for further investigations. IHRA has the potential for widespread improvement in clinical outcomes and for deployment in large public health programs across communities.
We have done more than 500 people's screening with this product in less than 3 days. It is quick, accurate and innovative. It's a good concept to know the health issues. Encourages our teams to be proactive about their health. Highly recommended.
This method is non-invasive and quick. Face scan using the thermal camera is a powerful innovation to conduct health checks. With this proven accuracy and ease of use, we envision this to be used for health checks for our clients.
IHRA adapts across multiple healthcare environments, supporting both preventive and clinical programs:
